What are the key details of the Pro Medicus (ASX:PME) contract with the University of Maryland?

Pro Medicus has signed a five-year, A$23 million deal with the University of Maryland Medical System (UMMS) via its subsidiary, Visage Imaging. The agreement involves deploying the Visage 7 Enterprise Imaging Platform, including its Viewer and Workflow modules, across the entire UMMS network.

Why is this contract significant for Pro Medicus (ASX:PME) shareholders?

This deal reinforces Pro Medicus’ dominant position in the North American health informatics market and proves its ability to win large-scale academic medical centre contracts. By transitioning a major system like UMMS to the cloud, PME demonstrates the scalability of its Visage 7 platform.

How does the transaction-based licensing model work for Pro Medicus (ASX:PME)?

The UMMS contract is built on a transactional model, meaning Pro Medicus earns revenue based on the volume of medical images processed or examined. This offers significant "blue sky" potential; if UMMS increases its diagnostic volumes or expands its network, PME’s revenue from this specific deal could exceed the base $23 million estimate.

What specific technology is being deployed in the University of Maryland deal?

The University of Maryland Medical System will implement the Visage 7 Enterprise Imaging Platform, specifically utilizing the Visage 7 Viewer and Visage 7 Workflow. This tech stack allows for "thin-client" streaming, meaning massive imaging files can be viewed quickly without needing heavy local hardware.

Which hospitals are included in the Pro Medicus (ASX:PME) North American expansion?

The rollout covers the extensive UMMS network, including the University of Maryland Medical Centre and the Marlene and Stewart Greenebaum Comprehensive Cancer Centre. It also includes the world-renowned R Adams Cowley Shock Trauma Centre.

What is the timeline for the Pro Medicus (ASX:PME) rollout at UMMS?

Planning for the implementation is set to begin immediately, following Visage’s established cloud-based rollout protocols. The company has targeted early 2027 for the "go-live" date, when the system becomes fully operational for diagnostic interpretation.

Does this news change the long-term investment thesis for Pro Medicus (ASX:PME)?

This news strengthens the "sticky" SaaS-style growth narrative for PME by adding another high-profile tier-one client to its portfolio. The shift of large medical systems toward cloud-native architectures acts as a tailwind for Pro Medicus, which is a first-mover in this space.

What are the primary risks for Pro Medicus (ASX:PME) following this announcement?

The main risk is execution delay; if the 2027 "go-live" date is pushed back, it could defer the expected revenue ramp-up. Additionally, because the contract is transaction-based, a broader decline in elective surgeries or hospital visits could theoretically impact the "upside" of the deal.

Health

Image for illustrative purposes only. Not a real photo.

Pro Medicus secures $23M University of Maryland contract

Written by Brie CarterPublished Apr 8, 2026, 1:31 AMLast Updated Jul 6, 2026, 10:30 AM

Pro Medicus (ASX:PME) announced an expansion of its North American footprint, securing a five-year, $23 million contract with the University of Maryland Medical System.

The agreement, executed through Pro Medicus' wholly-owned subsidiary Visage Imaging, marks a pivotal shift for the healthcare network as it transitions to a unified, cloud-based enterprise imaging strategy.

Under the terms of the deal, UMMS will implement the full Visage 7 Enterprise Imaging Platform, including the Visage 7 Viewer and Visage 7 Workflow.

The implementation will provide a single, streamlined diagnostic interpretation interface across the entire UMMS network, which encompasses renowned institutions such as the University of Maryland Medical Centre and the R Adams Cowley Shock Trauma Centre.

The transition to a cloud-native architecture is expected to enhance operational efficiency and diagnostic speed across the system’s diverse clinical sites.

The contract is built upon a transaction-based licensing model, offering Pro Medicus potential revenue upside as diagnostic volumes scale.

Rollout planning is scheduled to commence immediately, leveraging Visage’s established cloud implementation protocols to ensure a seamless transition.

The medical system anticipates a full "go-live" in early 2027.

At the time of reporting, Pro Medicus’ share price was $132.12.

Pro Medicus secures $23M University of Maryland contract

Perguntas frequentes

Ativos relacionados a notícia